Covista stock jumped 13.5% to US$140.98 today, and the move was all about margins. Investors responded to a full year adjusted EBITDA margin of 26.7% and a Q4 margin of 25.3%, both paired with Q4 revenue of US$501.4m. The share price reaction suggests traders are focusing on this as not just an enrollment story but also a profitability one.

The question now is whether that enthusiasm reflects a careful reading of the numbers or a momentum-driven response to one strong year of margin gains. The rest of the earnings package will show how solid that conviction is.

Is Covista a genuine bargain at a P/E of 17.9x while a DCF model points to US$294.23 per share, or is the market seeing something this headline miss? Compare the current price against our valuation analysis for Covista.

FY 2026 Earnings Summary

• Q4 2026 Revenue: US$501.4m vs. Q4 2025 US$457.1m (up 9.7%)
• Q4 2026 Net Income from Continuing Operations: US$72.2m vs. Q4 2025 US$54.5m (up 32.5%)
• Q4 2026 Basic EPS: US$2.12 vs. Q4 2025 US$1.51 (up 40.4%)
• FY 2026 Adjusted EBITDA Margin: 26.7% vs. FY 2025 25.7% (expanded by 1.0 percentage point)

Prefer clean charts instead of another wall of earnings tables and margin figures? See Covista's full financial picture with a visual breakdown of its valuation in the company report for Covista.

Evaluating Covista’s “Purpose at Scale” Bull Case

Bulls argue Covista can turn healthcare workforce shortages into profitable, scalable growth. The FY26 print hits several of the milestones that view depends on. Revenue of US$1.954b with adjusted EBITDA of US$521.7m and a 26.7% margin shows operating leverage is starting to come through, not just revenue growth. Adjusted EPS of US$8.25 and free cash flow of US$393m back the claim that this is an earnings and cash story, not just an enrollment story.

The enrollment pillar also looks intact. Management cited 12 consecutive quarters of enrollment growth, record levels at Walden and Chamberlain, and Q4 Walden revenue growth of 15.7% with enrollment up 14%. Chamberlain returned to total enrollment growth and kept pre licensure BSN growth rolling. The “Purpose at Scale” plan now rests on whether these trends can continue as campus and technology investments step up in FY27.

Compare Covista’s margin story and cash generation against what institutional desks are pricing in. See the consensus price target analysis for Covista to gauge whether Wall Street expects this earnings profile to continue supporting the current valuation.

Covista Bear Worries On Capital Intensity Still Unproven

Bears argue Covista is overbuilding capacity, tying up capital in new campuses and digital projects that will dilute free cash flow and returns. This set of results does not fully support that fear, but it also does not close the book on it. Free cash flow of US$393m and operating cash flow of US$471m sit awkwardly next to concerns about weakening cash conversion. Net leverage of 0.5x also contradicts the idea that the balance sheet is being stretched to fund growth.

The missed milestone is different. Bears expected clearer evidence that capital intensity is already compressing margins. Instead, adjusted EBITDA margin reached 26.7% and management still guides to only modest margin expansion in FY27 while capex rises. That leaves a key bearish claim unresolved. The cash engine is intact for now, but the returns from the next wave of campus and tech spending remain untested rather than disproven.

After such a strong cash print, the real question is whether Covista’s next investment cycle quietly erodes that profile. Review the risk analysis for Covista which shows 1 important warning sign

Stay Ahead Of Your Next Move

If Covista's mix of margin strength and cash generation has your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch for a more attractive entry or exit point. Once you hold the stock, use the Portfolio Command Center to cut through market noise and get focused alerts on the updates that matter to your thesis. Over the longer term, tap into crowd insights and different angles on Covista through the Community so you are not thinking in a vacuum. That way you can spot fresh catalysts and emerging risks earlier and stay a step ahead of the wider market.

Seeking Alternatives Beyond Covista Stock?

Fresh ideas do not stay quiet for long. Some stocks are already building breakout momentum while they remain under the radar for now. Before the crowd catches up, act now.

• Spot companies quietly building staying power and resilient balance sheets, then scan the curated list of solid balance sheet and fundamentals stocks (49 results) before that quality gets fully priced in by the wider market.
• Ride early momentum in income opportunities by checking hand picked 8 dividend fortresses before yields get compressed and prices start moving away from your ideal entry range.
• Get ahead of the next wave in machine learning infrastructure by reviewing carefully filtered 55 AI infrastructure stocks while these enablers of AI growth are still being priced like side stories.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.